Weekly Mind Reader: Xylazine Masks Benzodiazepine Withdrawal

by Denis Storey
February 9, 2024 at 11:10 AM UTC

This week begins with a review of the latest internet gaming disorder research, a case report of tapentadol-induced hallucinations, and a novel way to identify face blindness.

Primary Care Companion just published a case study that highlights the potentially lethal consequences of xylazine adulteration in opioids, benzodiazepines, and cocaine.

Xylazine Masks Benzodiazepine Withdrawal

This case study reported on a 35-year-old man with a history of polysubstance use disorder, including opioids, cocaine, benzodiazepines, THC, methamphetamine, and tobacco.

After a recent hospitalization for opioid overdose, he presented with cyanosis and doctors managed to successfully resuscitate him. Despite reporting benzodiazepine withdrawal symptoms, treatment was not initiated due to conflicting clinical indicators.

However, the patient subsequently experienced a seizure, attributed to benzodiazepine withdrawal masked by xylazine, an adulterant in his drug supply. Testing revealed impurities including xylazine, fentanyl, and bromazolam.

This case underscores the importance of monitoring patients for withdrawal symptoms, especially in those using multiple substances. It also highlights the need for drug testing to identify impurities in the community drug supply.

Xylazine, known as “tranq,” is a potent veterinary anesthetic increasingly found as an adulterant in opioids, benzodiazepines, and cocaine. Its central nervous system effects include sedation, analgesia, and muscle relaxation, potentially masking withdrawal symptoms without providing necessary GABAergic effects.

This case, possibly the first describing xylazine masking benzodiazepine withdrawal leading to a seizure, emphasizes the importance of vigilant monitoring for withdrawal symptoms, even after the acute phase, and the value of drug testing to identify impurities. It also suggests the need for increased awareness and recognition of the dangers posed by xylazine in the community drug supply, as highlighted in recent public health reports.

IN OTHER PSYCHIATRY AND NEUROLOGY NEWS

  • Recognition of hypoactive delirium should prompt the search for its underlying etiologies, with initial attention paid to life-threatening or emergent causes.
  • Editor-in-Chief Marlene P. Freeman, MD, reflects on the importance of peer-reviewed research in today’s world and recognizes the contributions of JCP authors and peer reviewers over the past year.
  • Dr. Andrade reviews and discusses research on the relationship of sedentary behaviors to the development of dementia.
  • Super Bowl Sunday drives significant academic research into issues such as increased alcohol consumption and gambling addiction concerns.
  • Researchers in Taiwan have unearthed further evidence that women with polycystic ovary syndrome (PCOS) are more likely to attempt suicide.

NEW AT CME INSTITUTE

Click to earn free accredited CME credit.

Untangling the Complexity of Alzheimer Disease With Effective Diagnostic Tools and Novel Treatment Options

Best Practices for Management of Mental Health in Women: Focusing on Mood Disorders Throughout the Lifespan

Cognitive Impairment in Huntington Disease

Commentary

Learning by Doing: Can Our Collective Experiences as Clinicians Improve Mental Health Care?

Drs Rush and Tramontin discuss how simple outcomes, often patient reported, could facilitate evidence-based decision making by clinicians, administrators, and payors and provide the foundation for a learning health care system.

A. John Rush and others

Case Report

Treatment of Catatonia With Electroconvulsive Therapy in a Patient With Neuropsychiatric Systemic Lupus Erythematosus, Epilepsy, and Cerebral Palsy

The authors discuss a patient with neuropsychiatric systemic lupus erythematosus, epilepsy, and cerebral palsy who developed benzodiazepine-refractory catatonia and immunosuppression with complete resolution of symptoms after 20 ECT treatments.

Tyler J. Thompson and others